Biohit Oyj B Cash Flow Conversion Efficiency
Biohit Oyj B cash flow conversion efficiency. Based on the latest financial reports, Biohit Oyj B (BIOBV) has a cash flow conversion efficiency ratio of 0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€600.00K ≈ $701.46K USD) by net assets (€14.90 Million ≈ $17.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BIOBV market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Biohit Oyj B (2000–2025)
Cash flow conversion efficiency of Biohit Oyj B from 2000 to 2025. This chart illustrates how Biohit Oyj B's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIOBV live share price for real-time trading data and today's change.
Biohit Oyj B Cash Flow Conversion Ratio Explained
Biohit Oyj B cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biohit Oyj B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohit Oyj B ranked by their cash flow conversion efficiency. Review BIOBV cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pioneer Power Solutions Inc.
NASDAQ:PPSI
|
-0.033x |
|
Allakos Inc
NASDAQ:ALLK
|
-0.511x |
|
Korea Ind
KO:002140
|
0.119x |
|
HPP Holdings Bhd
KLSE:0228
|
0.034x |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
-0.001x |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
-0.387x |
|
Centric Holdings S.A
AT:CENTR
|
0.008x |
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
Annual Cash Flow Conversion Efficiency for Biohit Oyj B (2000–2025)
The table below shows the annual cash flow conversion efficiency of Biohit Oyj B from 2000 to 2025. Also see Biohit Oyj B balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.90 Million ≈ $17.42 Million |
€-700.00K ≈ $-818.37K |
-0.047x | -197.81% |
| 2024-12-31 | €12.20 Million ≈ $14.26 Million |
€586.00K ≈ $685.10K |
0.048x | -49.81% |
| 2023-12-31 | €9.43 Million ≈ $11.02 Million |
€902.00K ≈ $1.05 Million |
0.096x | -61.38% |
| 2022-12-31 | €7.46 Million ≈ $8.72 Million |
€1.85 Million ≈ $2.16 Million |
0.248x | +507.40% |
| 2021-12-31 | €7.30 Million ≈ $8.53 Million |
€-444.00K ≈ $-519.08K |
-0.061x | -2017.33% |
| 2020-12-31 | €8.70 Million ≈ $10.17 Million |
€-25.00K ≈ $-29.23K |
-0.003x | -150.46% |
| 2019-12-31 | €14.58 Million ≈ $17.05 Million |
€83.00K ≈ $97.04K |
0.006x | +197.28% |
| 2018-12-31 | €15.89 Million ≈ $18.58 Million |
€-93.00K ≈ $-108.73K |
-0.006x | +89.30% |
| 2017-12-31 | €17.24 Million ≈ $20.16 Million |
€-943.00K ≈ $-1.10 Million |
-0.055x | +76.07% |
| 2016-12-31 | €10.75 Million ≈ $12.57 Million |
€-2.46 Million ≈ $-2.87 Million |
-0.229x | +25.12% |
| 2015-12-31 | €10.31 Million ≈ $12.05 Million |
€-3.15 Million ≈ $-3.68 Million |
-0.305x | -12.65% |
| 2014-12-31 | €12.68 Million ≈ $14.82 Million |
€-3.44 Million ≈ $-4.02 Million |
-0.271x | -36.91% |
| 2013-12-31 | €22.45 Million ≈ $26.25 Million |
€-4.44 Million ≈ $-5.19 Million |
-0.198x | +20.99% |
| 2012-12-31 | €35.49 Million ≈ $41.49 Million |
€-8.89 Million ≈ $-10.39 Million |
-0.250x | -367.03% |
| 2011-12-31 | €52.85 Million ≈ $61.78 Million |
€4.96 Million ≈ $5.80 Million |
0.094x | -37.80% |
| 2010-12-31 | €13.00 Million ≈ $15.20 Million |
€1.96 Million ≈ $2.29 Million |
0.151x | -31.23% |
| 2009-12-31 | €12.75 Million ≈ $14.90 Million |
€2.80 Million ≈ $3.27 Million |
0.219x | +130.61% |
| 2008-12-31 | €12.49 Million ≈ $14.60 Million |
€1.19 Million ≈ $1.39 Million |
0.095x | +8.29% |
| 2007-12-31 | €11.84 Million ≈ $13.84 Million |
€1.04 Million ≈ $1.22 Million |
0.088x | +1078.15% |
| 2006-12-31 | €13.41 Million ≈ $15.68 Million |
€100.00K ≈ $116.91K |
0.007x | -82.44% |
| 2005-12-31 | €14.25 Million ≈ $16.66 Million |
€605.00K ≈ $707.31K |
0.042x | -73.18% |
| 2004-12-31 | €14.14 Million ≈ $16.53 Million |
€2.24 Million ≈ $2.62 Million |
0.158x | +158.63% |
| 2003-12-31 | €14.10 Million ≈ $16.49 Million |
€863.00K ≈ $1.01 Million |
0.061x | -46.71% |
| 2001-12-31 | €16.33 Million ≈ $19.10 Million |
€1.88 Million ≈ $2.19 Million |
0.115x | +110.71% |
| 2000-12-31 | €98.02 Million ≈ $114.60 Million |
€5.34 Million ≈ $6.25 Million |
0.055x | -- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more